Deals
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Benelux’ largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing SkylineDx’ market potential of over $1 billion annually based on their current progress in the melanoma field.
Citing unnamed sources “familiar with the matter,” Reuters said that the company will have no choice but to file for bankruptcy should a settlement not be agreed upon.
A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited are pleased to announce that its interim results for the period ended 30 June 2019
Esperion announced that, on August 27, 2019, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted stock units to eighteen new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan.
MGB Biopharma announces the completion of its latest funding round.
Semma will become a separate operating subsidiary of Vertex. Semma is working to advance Melton’s methodology for creating billions of functional, insulin-producing beta cells.
Ergomed plc will announce its interim results for the six months ending 30 June 2019 on 25September 2019.
Vivoryon Therapeutics AG announced its financial results for the first six months of 2019 ending June 30.
MyoKardia, Inc., announced its participation in the following upcoming investor conferences:
The first half of the year has been characterized by continued work to develop the company’s innovative projects in two treatment areas, both of which have significant medical needs because the current treatment options are less effective or non-existent.